Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
The company announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on March 26, 2026, to discuss the development pathway for suspected heparin-induced thrombocytopenia (HIT).
The regulatory milestone follows robust Phase 2 clinical data, which demonstrated a greater than 25% absolute reduction in thrombotic events compared to current standard-of-care treatments.
Management indicated that the FDA provided constructive feedback on the proposed trial design, and the company is currently incorporating these insights into a final Phase 3 pivotal protocol intended to support a future New Drug Application (NDA).
Financially, Cadrenal reported a net loss of $3 million for the fourth quarter of 2025.
As of December 31, 2025, the company held $4 million in cash and cash equivalents.
To support the intensive capital requirements of a global Phase 3 program, Cadrenal confirmed that it is actively evaluating various financing and strategic alternatives, which may include equity raises, licensing agreements, or co-development partnerships.
CAD-1005 is designed as a novel therapy for patients with HIT, a life-threatening immune-mediated complication of heparin therapy that often leads to severe clotting.
Current treatment options are limited and carry significant bleeding risks, positioning CAD-1005 as a potential first-in-class solution for a high-unmet-need hospital market.